Biogen (BIIB) analyst forecast and price target
Analyst forecast
Consensus of 37 analyst ratings
Based on 16 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| JP Morgan | Upgraded | Neutral → Overweight | $300.00 from $210.00 | Oct 12, 2026 |
| UBS | Maintained | Buy | $270.00 from $240.00 | Oct 9, 2026 |
| RBC Capital | Maintained | Outperform | $256.00 from $260.00 | Oct 8, 2026 |
| HSBC | Maintained | Reduce | $175.00 from $165.00 | Sep 10, 2026 |
| Piper Sandler | Maintained | Overweight | $245.00 from $225.00 | Sep 3, 2026 |
| RBC Capital | Maintained | Outperform | $260.00 from $240.00 | Aug 25, 2026 |
| Wolfe Research | Upgraded | Peer Perform → Outperform | $300.00 | Aug 13, 2026 |
| Mizuho | Maintained | Outperform | $241.00 from $221.00 | Aug 4, 2026 |
| Citigroup | Maintained | Neutral | $215.00 from $200.00 | Aug 3, 2026 |
| Wedbush | Maintained | Neutral | $215.00 from $201.00 | Jul 30, 2026 |
| Canaccord Genuity | Maintained | Buy | $248.00 from $245.00 | Jul 30, 2026 |
| TD Cowen | Maintained | Buy | $225.00 from $215.00 | Jul 30, 2026 |
| RBC Capital | Maintained | Outperform | $240.00 from $242.00 | Jul 30, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $231.00 from $222.00 | Jul 30, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $251.00 from $237.00 | Jul 30, 2026 |
| UBS | Maintained | Buy | $240.00 from $225.00 | Jul 30, 2026 |
| Barclays | Maintained | Equal-Weight | $200.00 from $185.00 | Jul 29, 2026 |
| B of A Securities | Maintained | Neutral | $215.00 from $217.00 | Jul 21, 2026 |
| Guggenheim | Maintained | Buy | $280.00 from $260.00 | Jul 21, 2026 |
| Truist Securities | Upgraded | Hold → Buy | $235.00 from $190.00 | Jul 13, 2026 |
Frequently asked questions
What is the price target for BIIB stock?
The average 12-month analyst price target for Biogen (BIIB) is $241.69, with a high estimate of $300.00 and a low of $175.00, across 16 analysts.
Is BIIB a buy, sell, or hold?
Analysts covering Biogen currently average a Buy rating: 24 buy, 12 hold and 1 sell, from 37 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for BIIB?
The average price target of $241.69 implies 3.80% upside from the last price of $232.83.
What is the latest analyst rating on BIIB?
On Oct 12, 2026, JP Morgan upgraded Biogen to Overweight with a price target of $300.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.